Strategies for cancer gene therapy

10.1172/JCI116850

10.1021/bi00025a023

10.1111/j.1432-1033.1996.0582z.x

10.1021/bi9718191

10.1021/bi972399i

10.1016/S0093-7754(01)90158-7

10.1007/s00280-001-0385-3

Snyder DS, 1997, Ribozyme‐mediated inhibition of a Philadelphia chromosome‐positive acute lymphoblastic leukemia cell line expressing the p190 bcr‐abl oncogene, Biol Blood Marrow Transplant, 3, 179

10.1038/sj.cgt.7700372

Jiang WG, 2001, A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c‐MET and reduces migration and invasiveness of breast cancer cells, Clin Cancer Res, 7, 2555

10.1096/fj.01-0421fje

Suwanal H, 2002, A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RARalpha mRNA, Int J Oncol, 20, 127

10.1002/mc.10017

10.1038/sj.onc.1202190

Alvarez RD, 2000, A cancer gene therapy approach utilizing an anti‐erbB‐2 single‐chain antibody‐encoding adenovirus (AD21): A phase 1 trial, Clin Cancer Res, 6, 3081

10.1016/S0022-1759(02)00035-2

10.1016/S0039-6060(97)90036-2

10.1212/WNL.50.5.1307

Minaguchi T, 1999, Growth suppression of human ovarian cancer cells by adenovirus‐mediated transfer of the PTEN gene, Cancer Res, 59, 6063

10.1038/sj.cgt.7700227

10.1006/mcne.2000.0949

10.1089/104303402317322311

10.1038/sj.cgt.7700480

10.1038/sj.gt.3301388

10.1038/sj.cgt.7700463

10.1038/sj.cgt.7700497

10.1038/sj.cgt.7700474

10.1016/S1471-4914(02)02317-1

10.2174/1566523023348101

Insug O, 2002, A dendritic cell vaccine induces protective immunity to intracranial growth of glioma, Anticancer Res, 22, 613

Simons JW, 1998, Ex‐vivo gene therapy using cytokine‐transduced tumor vaccines: Molecular and clinical pharmacology, Sem Oncol, 25, 661

10.1038/sj.cgt.7700240

10.1038/sj.cgt.7700435

10.1038/sj.cgt.7700224

10.1007/s00268-002-4053-5

Freeman SM, 1993, The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res, 53, 5274

Wygoda MR, 1997, Protection of herpes simplex virus thymidine kinase‐transduced cells from ganciclovir‐mediated cytotoxicity by bystander cells: The Good Samaritan effect, Cancer Res, 57, 1699

Moolten F, 1986, Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy, Cancer Res, 46, 5276

10.1073/pnas.74.12.5716

Freytag SO, 2002, Phase I study of replication‐competent adenovirus‐mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer, Cancer Res, 62, 4968

10.1182/blood.V74.1.152.152

Ward M, 1994, Transfer and expression of the human multiple drug resistance gene in human CD34+ cells, Blood, 84, 1408, 10.1182/blood.V84.5.1408.1408

10.1007/BF01878359

10.1200/JCO.1998.16.1.165

Cowan KH, 1999, Paclitaxel chemotherapy after autologous stem‐cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in meta static breast cancer patients, Clin Cancer Res, 5, 1619

Schiedimeier B, 2000, Quantitative assessment of retroviral transfer of the human mulitdrug resistance I gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice, Blood, 95, 1237, 10.1182/blood.V95.4.1237

10.1038/76225

10.1002/ijc.10206

10.1016/0092-8674(91)90141-K

10.1146/annurev.bi.62.070193.002125

10.1007/BF01878359

10.1006/mthe.2000.0236

10.1038/sj.gt.3300720

10.1128/MCB.10.8.4239

10.1002/j.1460-2075.1993.tb05858.x

10.1089/hum.1998.9.1-63

Povey J, 1998, Enhanced retroviral transduction of 5‐fluorouracil‐resistant human bone marrow (stem) cells using a genetically modified packaging cell line, Blood, 92, 4080, 10.1182/blood.V92.11.4080

10.1016/0092-8674(95)90488-3

10.1073/pnas.94.19.10319

10.1126/science.272.5259.263

10.1128/jvi.70.1.217-222.1996

10.1016/0092-8674(93)90231-E

10.1093/emboj/16.9.2294

10.1126/science.275.5304.1320

10.1016/0168-9525(96)40031-2

10.1146/annurev.mi.49.100195.004111

Yang Y, 1995, Clearance of adenovirus‐infected hepatocytes by MHC class 1 restricted CD4+ CTLs in vivo, J Immunol, 155, 2564, 10.4049/jimmunol.155.5.2564

10.1128/JVI.74.9.3941-3947.2000

10.1089/10430340252792503

10.1073/pnas.87.6.2211

Rutledge EA, 1997, Adeno‐associated virus vector integration junctions, J Virol, 71, 8429, 10.1128/jvi.71.11.8429-8436.1997

10.1128/JVI.76.9.4580-4590.2002

Peplinski GR, 1998, Vaccinia virus for human gene therapy, Surg Oncol Clin N Am, 7, 575, 10.1016/S1055-3207(18)30261-8

Hodge JW, 1994, Induction of antitumor immunity by recombinant vaccinia viruses expressing B7‐1 or B7‐2 costimulatory molecules, Cancer Res, 54, 5552

10.1016/S0022-5347(05)65755-2

10.1006/mthe.2001.0493

McCart JA, 2001, Systemic cancer therapy with a tumor‐selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes, Cancer Res, 61, 8751

10.1093/brain/120.7.1245

10.1146/annurev.mi.49.100195.003331

10.1073/pnas.93.21.11319

10.1089/104303401750195836

10.1126/science.1690918

10.1159/000020281

Felgner JH, 1994, Enhanced gene delivery system and mechanism studies with a novel series of cationic lipid formulations, J Biol Chem, 269, 2550, 10.1016/S0021-9258(17)41980-6

Yotsuyanagi T, 1998, Cationic liposomes in gene delivery, Nippon Rinsho, 56, 705

10.1016/S0006-2952(97)00872-1

10.1016/0005-2736(91)90162-2

10.1073/pnas.84.22.7851

10.1016/0014-4827(86)90056-X

10.1073/pnas.93.21.11421

10.1073/pnas.88.10.4255

Wu CH, 1989, Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo, J Biol Chem, 264, 16985, 10.1016/S0021-9258(18)71447-6

10.1172/JCI116845

10.1073/pnas.89.13.6099

Curiel DT, 1994, High‐efficiency gene transfer employing adenovirus–polylysine–DNA complexes, Nat Immunol, 13, 141

Forsayeth JR, 1994, Adenovirus‐mediated transfection of cultured cells, Biotechniques, 17, 354

10.1073/pnas.89.13.6094

Raja‐Walia R, 1995, Enhancement of liposome‐mediated gene transfer into vascular tissue by replication deficient adenovirus, Gene Ther, 2, 521

10.1038/sj.cgt.7700485

10.1021/bc025541n

10.1096/fj.02-0088com